Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Short Interest Update

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the recipient of a significant growth in short interest in November. As of November 15th, there was short interest totalling 101,400 shares, a growth of 53.6% from the October 31st total of 66,000 shares. Currently, 0.4% of the company’s shares are sold short. Based on an average trading volume of 139,700 shares, the short-interest ratio is currently 0.7 days.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Bolt Biotherapeutics in a research note on Wednesday, November 13th. Five equities research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, Bolt Biotherapeutics currently has a consensus rating of “Hold” and an average target price of $3.50.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Assenagon Asset Management S.A. purchased a new stake in shares of Bolt Biotherapeutics during the second quarter worth about $26,000. Acuitas Investments LLC grew its stake in Bolt Biotherapeutics by 21.7% during the 2nd quarter. Acuitas Investments LLC now owns 630,507 shares of the company’s stock valued at $473,000 after acquiring an additional 112,555 shares in the last quarter. Finally, FMR LLC grew its stake in Bolt Biotherapeutics by 33.2% during the 3rd quarter. FMR LLC now owns 115,386 shares of the company’s stock valued at $75,000 after acquiring an additional 28,773 shares in the last quarter. Institutional investors and hedge funds own 86.70% of the company’s stock.

Bolt Biotherapeutics Stock Performance

NASDAQ BOLT traded up $0.01 on Friday, hitting $0.64. The stock had a trading volume of 132,236 shares, compared to its average volume of 165,235. The business’s fifty day moving average price is $0.63 and its 200 day moving average price is $0.70. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.16 and a quick ratio of 3.16. Bolt Biotherapeutics has a 52-week low of $0.54 and a 52-week high of $1.56.

Bolt Biotherapeutics (NASDAQ:BOLT) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.04). The company had revenue of $1.14 million for the quarter, compared to analysts’ expectations of $1.02 million. Bolt Biotherapeutics had a negative net margin of 665.56% and a negative return on equity of 69.46%. Sell-side analysts anticipate that Bolt Biotherapeutics will post -1.61 EPS for the current fiscal year.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.